Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients. The importance of biosimilars only continues ...

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients. The importance of biosimilars only continues ...

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

Eli Lilly (NYSE: LLY) has a strong pipeline of new medicines that could increase the stock price. *Stock prices used were the afternoon prices of May 15, 2025. The video was published on May 17 ...

Eli Lilly applied for a tax abatement under the Texas Jobs, Energy, Technology and Innovation program, the Houston Business Journal reported. This initiative—the JETI program—gives a 10-year ...

Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.

Eli Lilly (NYSE: LLY) is gaining market share in a lucrative market that could be a catalyst for a stock price increase. *Stock prices used were the afternoon prices of May 14, 2025. The video was ...